News
Free Guide: FDA Meeting Mastery: A Guide to Go From Request to Regulatory Win
Every FDA interaction is high-stakes. The right preparation turns a meeting request into a success.
Whether ...
Case Study – From Pre-IND to Phase 3: A Japan Biotech’s Path to FDA Alignment
This case study explores how J-Pharma partnered with Uniphar | Development to advance its lead oncology program ...
Uniphar to Attend BioJapan 2026
Uniphar Development is excited to announce our participation in BioJapan 2026.
Location: Pacifico Yokohama, ...
Uniphar to Sponsor NCLifeSci Annual Meeting 2026
Uniphar Development, alongside our Uniphar Clinical and Uniphar Logistics colleagues, is proud to be a Silver ...
J-Pharma Highlights Global Development Strategy and Uniphar Development Partnership in BioSpectrum Asia Interview
J-Pharma was recently featured in BioSpectrum Asia, where Max Yoshitake, President & CEO, discussed the ...
J Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment
Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients ...
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
- New integration aligns U.S. operations, unifying RRD Biopharma Development, Uniphar Clinical, Diligent Health ...
FDA’s New Commissioner’s National Priority Voucher Program: A Game-Changer for Strategic Sponsors
The Opportunity Is Real—But So Are the Requirements
On June 17, FDA Commissioner Marty Makary announced the ...
RRD Biopharma Development to Attend BIO International Convention 2025
RRD Biopharma Development is excited to announce our participation in the BIO International Convention 2025, ...
The 505(b)(2) Platform Webinar Recording: “505(b)(2) Right-First-Time Strategy for Today’s FDA”
In today's dynamic regulatory environment, marked by potential organizational shifts and unpredictable timelines ...
RRD to Attend American Society of Clinical Oncology 2025
RRD Biopharma Development will be attending the 2025 ASCO Annual Meeting. We’re excited to engage with oncology ...
Cancer Drug Development Expert Eric Rowinsky, M.D., to Serve as Chief Medical Officer at RRD Biopharma Development, part of Uniphar
ROCKVILLE, Md., May 14, 2025 — RRD Biopharma Development (RRD), part of Uniphar, a specialized product development ...
